Hennion & Walsh Asset Management Inc. bought a new position in shares of SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 98,347 shares of the company’s stock, valued at approximately $567,000.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC increased its position in SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after acquiring an additional 4,155 shares during the period. Dimensional Fund Advisors LP increased its holdings in SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the period. Principal Financial Group Inc. increased its holdings in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the first quarter valued at $50,000. Finally, Squarepoint Ops LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth $49,000. 31.59% of the stock is owned by institutional investors.
Insider Activity
In other news, CEO Ross Muken sold 9,838 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the transaction, the chief executive officer owned 670,651 shares of the company’s stock, valued at $3,500,798.22. This represents a 1.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jurgi Camblong sold 50,069 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the completion of the sale, the chief executive officer directly owned 3,601,493 shares of the company’s stock, valued at $20,888,659.40. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 318,592 shares of company stock worth $1,952,315. Company insiders own 4.88% of the company’s stock.
SOPHiA GENETICS Stock Performance
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages have commented on SOPH. HC Wainwright lifted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.00.
Read Our Latest Analysis on SOPH
SOPHiA GENETICS Company Profile
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Stories
- Five stocks we like better than SOPHiA GENETICS
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding SOPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report).
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
